Ayala Pharmaceuticals Inc (ADXS)

[ubmmg]

Wednesday morning cold shower:

A year ago, Advaxis had a poster presentation at ESGO in Vienna, Austria.
https://ir.advaxis.com/press-release/clinical-data-updates/advaxis-axalimogene-filolisbac-data-selected-poster
As far I as recall, there was a large Advaxis crowd in Austria, all pumped up with the upcoming submission for an EU approval, and etc. There was also an interview with Drs Marth and Ghamande (Immunotherapy: A New Strategy for the Treatment of Cervical Cancer. Interview with Dr. Christian Marth and Dr. Sharad Ghamande)
https://www.mdpi.com/2076-3271/6/1/9/htm
Just read if you haven't, but I cannot escape the notion the company tried too hard to pump this event up in anticipation of approval and hoping to influence the EU scientific community.
Snip:
"Q4. What is your vision for the future regarding this specific drug and immunotherapy in general?
R4. Most cervical cancers are caused by high-risk HPV, and have E6 and E7 oncogenes that are constitutively expressed, tumor-specific, and functionally important. That means cervical cancer can be attacked by different immunotherapy approaches more successfully than other gynecological cancers. We think that, along with ADXS-11, immunotherapy will play a big part in treating cervical cancer—mirroring the success of HPV vaccines in preventing cervical cancer."
And just few months later, they pulled EMA submission, and threatened to shelve AXAL altogether (maybe they did). What a complete 180-degree turn of the events. Money thrown away on expensive trips, expensive prep work, all in vain. BTW, it was our money, not theirs.
End of cold shower.